Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Pioglitazone418 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A27577 | 17935056 | Diab Vasc Dis Res | The role of fenofibrate in clinical practice. | 2007 | Details |
| A27587 | 17983937 | Endocrinol Metab Clin North Am | Use of insulin sensitizers in NASH. | 2007 | Details |
| A27597 | 17950097 | Metabolism | Regulation of adiponectin receptor expression in human liver and a hepatocyte cell line. | 2007 | Details |
| A27603 | 17928738 | J Pharmacol Sci | Life style-related diseases of the digestive system: gene expression in nonalcoholic steatohepatitis patients and treatment strategies. | 2007 | Details |
| A27723 | 17560678 | J Hepatol | Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. | 2007 | Details |
| A27850 | 17253544 | Cochrane Database Syst Rev | Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. | 2007 | Details |
| A27968 | 16845716 | J Zhejiang Univ Sci B | Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats. | 2006 | Details |
| A28044 | 16610015 | World J Gastroenterol | Treatment of nonalcoholic fatty liver disease. | 2006 | Details |
| A28077 | 16503761 | Expert Opin Investig Drugs | Recent findings concerning thiazolidinediones in the treatment of diabetes. | 2006 | Details |
| A28165 | 16231594 | Eur Rev Med Pharmacol Sci | The treatment of NAFLD. | 2006 | Details |
| A28339 | 15598336 | Pediatr Transplant | Non-alcoholic steatohepatitis in children. | 2004 | Details |
| A28428 | 15017657 | Clin Gastroenterol Hepatol | Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. | 2003 | Details |
| A28430 | 15013444 | Biochem Biophys Res Commun | Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. | 2004 | Details |
| A28459 | 14585234 | Curr Treat Options Gastroenterol | Treatment of Nonalcoholic Fatty Liver Disease. | 2003 | Details |
| A28650 | 35183762 | Nanomedicine | Platelet-neutrophil hybrid membrane-coated gelatin nanoparticles for enhanced targeting ability and intelligent release in the treatment of non-alcoholic steatohepatitis. | 2022 | Details |
| A29196 | 34430785 | Hepatol Commun | Deuterium-Stabilized (R)-Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity. | 2021 | Details |
| A29546 | 33903842 | Cureus | Clinical Management of Nonalcoholic Steatohepatitis (NASH) With the Use of Thiazolidinediones and the Additive Effect of Thiazolidinediones and a GLP-1 Agonist: Case Series. | 2021 | Details |
| A30665 | 32025605 | Hepatol Commun | Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice. | 2019 | Details |
| A31304 | 30846912 | Gastroenterol Hepatol (N Y) | Pharmacologic Management of Nonalcoholic Steatohepatitis. | 2018 | Details |
| A31375 | 30705600 | Diabetes Metab Syndr Obes | Effects of duodenal-jejunal bypass surgery in ameliorating nonalcoholic steatohepatitis in diet-induced obese rats. | 2019 | Details |
| A31405 | 30633968 | Eur J Pharm Sci | Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats. | 2019 | Details |
| A31531 | 30367397 | J Gastrointest Surg | Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. | 2018 | Details |
| A32811 | 27421062 | Hepatol Res | Pharmacological evaluation of pioglitazone and candesartan cilexetil in a novel mouse model of non-alcoholic steatohepatitis, modified choline-deficient, amino acid-defined diet fed low-density lipoprotein receptor knockout mice. | 2016 | Details |
| A32906 | 27114939 | J Tradit Complement Med | Extract of a polyherbal formulation ameliorates experimental nonalcoholic steatohepatitis. | 2015 | Details |
| A33998 | 24669237 | Exp Ther Med | Effects of pioglitazone on nonalcoholic steatohepatitis in a patient with anorexia nervosa: A case report. | 2014 | Details |
| A34334 | 26201790 | Hepatol Int | The influence of pioglitazone on the plasma amino acid profile in patients with nonalcoholic steatohepatitis (NASH). | 2012 | Details |
| A34685 | 22882855 | Chin Med J (Engl) | Pioglitazone ameliorates nonalcoholic steatohepatitis by down-regulating hepatic nuclear factor-kappa B and cyclooxygenases-2 expression in rats. | 2012 | Details |
| A34702 | 22834991 | Hepatol Res | Altered expression and function of hepatic natural killer T cells in obese and diabetic KK-A(y) mice. | 2012 | Details |
| A35444 | 20662773 | Aliment Pharmacol Ther | Pioglitazone in the treatment of NASH: the role of adiponectin. | 2010 | Details |
| A35530 | 20427778 | N Engl J Med | Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. | 2010 | Details |
| A35799 | 19670459 | Hepatology | Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. | 2009 | Details |
| A36013 | 19205029 | Hepatology | Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-A(y) mice. | 2009 | Details |
| A36214 | 18718471 | Gastroenterology | Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. | 2008 | Details |
| A36291 | 18513333 | Hepatol Res | Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-beta1 in a cultured stellate cell line. | 2008 | Details |
| A36637 | 17559148 | Hepatology | The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. | 2007 | Details |
| A36710 | 17410441 | Dig Dis Sci | Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. | 2007 | Details |
| A36801 | 17241878 | Gastroenterology | Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. | 2006 | Details |
| A36967 | 16814613 | Clin Gastroenterol Hepatol | Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. | 2006 | Details |
| A36989 | 16768125 | Nihon Rinsho | [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance]. | 2006 | Details |
| A36994 | 16768114 | Nihon Rinsho | [PPAR and NASH]. | 2006 | Details |
| A37276 | 16085455 | Hepatol Res | The peroxisome proliferator-activated receptor-gamma agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, l-amino acid-defined diet. | 2005 | Details |
| A37463 | 15625656 | Clin Gastroenterol Hepatol | A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. | 2004 | Details |
| A37708 | 15066643 | Eur J Intern Med | Non-alcoholic steatohepatitis: review of a growing medical problem. | 2004 | Details |
| A37753 | 14752837 | Hepatology | A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. | 2004 | Details |
| A38179 | 11965828 | Int J Clin Pract Suppl | Thiazolidinedione hepatotoxicity: a class effect? | 2000 | Details |
| A42304 | 34918436 | Diabetes Obes Metab | Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial. | 2021 | Details |
| A43318 | 31984804 | Expert Opin Investig Drugs | NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges. | 2020 | Details |
| A43845 | 30706731 | Diab Vasc Dis Res | Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. | 2019 | Details |
| A44145 | 29598814 | Curr Vasc Pharmacol | Editorial: Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and Mortality. | 2018 | Details |
| A44398 | 28707804 | Aliment Pharmacol Ther | Letter: clinical response to pioglitazone in nonalcoholic steatohepatitis [NASH] treatment-use of pharmacokinetic surrogate. | 2017 | Details |
| A44409 | 28692223 | Rev Med Suisse | 2016 | Details | |
| A44410 | 28692197 | J Gastroenterol Hepatol | The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. | 2018 | Details |
| A44496 | 28468762 | Gut | Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus-authors' response. | 2017 | Details |
| A44512 | 28408383 | Gut | Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus. | 2017 | Details |
| A44515 | 28397875 | Am J Gastroenterol | Treatment of NASH: What Helps Beyond Weight Loss? | 2017 | Details |
| A44553 | 28241265 | JAMA Intern Med | The Role of Pioglitazone in the Management of Nonalcoholic Steatohepatitis: Are We There Yet? | 2017 | Details |
| A44567 | 28166556 | Ann Intern Med | Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis. | 2017 | Details |
| A44568 | 28166555 | Ann Intern Med | Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis. | 2017 | Details |
| A44569 | 28166554 | Ann Intern Med | Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis. | 2017 | Details |
| A44629 | 27880988 | Hepatology | Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges. | 2017 | Details |
| A44718 | 27594084 | Metabolism | Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists. | 2016 | Details |
| A44721 | 29737646 | Diabetes Self Manag | THE HEPATITIS/DIABETES CONNECTION The Effect of Hep C cures on Type 2 diabetes still unknown. | 2016 | Details |
| A44781 | 27322943 | Ann Intern Med | Pioglitazone for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes. | 2016 | Details |
| A44782 | 27322890 | Ann Intern Med | Pioglitazone: An Addition to Our Toolbox for Patients With Diabetes and Nonalcoholic Steatohepatitis? | 2016 | Details |
| A44858 | 27053230 | Diabetologia | EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. | 2016 | Details |
| A45611 | 23680744 | Hosp Pract (1995) | Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. | 2013 | Details |
| A45779 | 22801247 | J Investig Med | Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes. | 2012 | Details |
| A45813 | 22612529 | J Vet Pharmacol Ther | Pharmacokinetics of pioglitazone in lean and obese cats. | 2012 | Details |
| A46031 | 21480350 | Hepatology | Insulin sensitizers in nonalcoholic steatohepatitis. | 2011 | Details |
| A46444 | 18619079 | Am Fam Physician | Gastrointestinal complications of diabetes. | 2008 | Details |
| A46603 | 17354303 | N Engl J Med | Pioglitazone in nonalcoholic steatohepatitis. | 2007 | Details |
| A46645 | 16932311 | Nat Clin Pract Endocrinol Metab | Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance. | 2006 | Details |
| A46690 | 16510031 | Curr Gastroenterol Rep | New treatments for nonalcoholic fatty liver disease. | 2006 | Details |
| A46781 | 15611492 | Ann Intern Med | Narrative review: hepatobiliary disease in type 2 diabetes mellitus. | 2004 | Details |
| A46802 | 15262299 | Endocrinol Metab Clin North Am | Glitazones and the management of insulin resistance: what they do and how might they be used. | 2004 | Details |
| A47770 | 32213649 | Endocrinol Diabetes Metab Case Rep | The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide. | 2020 | Details |
| A47960 | 28098353 | J Cell Physiol | The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. | 2017 | Details |
| A48006 | 26781175 | Mol Med Rep | TLR4‑dependent signaling pathway modulation: A novel mechanism by which pioglitazone protects against nutritional fibrotic steatohepatitis in mice. | 2016 | Details |
| A48042 | 25866507 | Gastroenterol Res Pract | Treatment of nonalcoholic steatohepatitis in adults: present and future. | 2015 | Details |
| A48165 | 20857543 | N Engl J Med | Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. | 2010 | Details |
| A48166 | 20855789 | Ann Intern Med | ACP Journal Club: vitamin E, but not pioglitazone, improved nonalcoholic steatohepatitis in nondiabetic patients. | 2010 | Details |
| A48168 | 20843257 | N Engl J Med | Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. | 2010 | Details |
| A48181 | 20530928 | Nihon Shokakibyo Gakkai Zasshi | A case of systemic lupus erythematosus with liver damage. | 2010 | Details |
| A48229 | 19172714 | Ann Intern Med | ACP Journal Club. Pioglitazone reduced liver injury and improved fasting glucose in nonalcoholic steatohepatitis without diabetes. | 2009 | Details |
| A48256 | 18335886 | Rev Med Suisse | [Highlights in hepatology]. | 2008 | Details |
| A48279 | 17590917 | Curr Diab Rep | Pioglitazone and nonalcoholic steatohepatitis. | 2007 | Details |
| A48286 | 17367243 | Arch Iran Med | A placebo-controlled trial of pioglitazone in patients with nonalcoholic steatohepatitis. | 2007 | Details |
| A48287 | 17354302 | N Engl J Med | Pioglitazone in nonalcoholic steatohepatitis. | 2007 | Details |
| A48288 | 17347462 | N Engl J Med | Pioglitazone in nonalcoholic steatohepatitis. | 2007 | Details |
| A48290 | 17326209 | Hepatology | Pioglitazone for patients with type 2 diabetes and nonalcoholic steatohepatitis. | 2007 | Details |
| A48294 | 17135591 | N Engl J Med | Thiazolidinediones for nonalcoholic steatohepatitis--promising but not ready for prime time. | 2006 | Details |
| A48295 | 17135584 | N Engl J Med | A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. | 2006 | Details |
| A48297 | 17038787 | Nihon Yakurigaku Zasshi | [PPAR gamma ligand pioglitazone as a therapeutic strategy in nonalcoholic steatohepatitis (NASH)]. | 2006 | Details |
| A48351 | 15625648 | Clin Gastroenterol Hepatol | Treatment of nonalcoholic steatohepatitis: antioxidants or insulin sensitizers? | 2004 | Details |
| A48745 | 29935912 | Diabetes Res Clin Pract | Corrigendum to "An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis" [Diab. Res. Clin. Pract. 135 (2018) 102-110]. | 2018 | Details |
| A48783 | 28895299 | J Diabetes Investig | Case of lipoatrophic diabetes induced by juvenile dermatomyositis. | 2017 | Details |
| A49069 | 24345559 | Obes Res Clin Pract | Index of the systemic balance of end products of glucocorticoid metabolism in fresh urine from humans. | 2009 | Details |
| A49192 | 14585066 | Expert Opin Drug Saf | Hepatotoxicity of thiazolidinediones. | 2003 | Details |
| A49230 | 35814516 | J Clin Exp Hepatol | Pharmacotherapeutic Impact on Nonalcoholic Steatohepatitis Histology: A Systematic Review and Network Meta-analysis. | 2022 | Details |
| A49296 | 35796150 | J Intern Med | Current treatment of non-alcoholic fatty liver disease. | 2022 | Details |